Лекарственная болезнь печени. Клинический случай цирроза печени на фоне приема нестероидных противовоспалительных препаратов
https://doi.org/10.26295/OS.2020.67.71.005
Аннотация
Лекарственные поражения печени составляют около 10% от всех побочных реакций макроорганизма, связанных с применением фармакологических препаратов. В статье приводятся основные механизмы лекарственного повреждения печени. Диагностика лекарственного повреждения печени часто бывает затруднительной и требует от врача не только необходимости тщательного сбора анамнеза пациента с развившимся заболеванием, но и хорошей ориентации в его клинических и морфологических проявлениях. Приводится клинический пример лекарственного цирроза печени, когда пациентка много лет злоупотребляла приемом различных нестероидных противовоспалительных препаратов, что привело к фатальному исходу.
Об авторах
Е. Ю. Плотникова
ФГБОУ ВО КемГМУ МЗ РФ
Россия
Россия
Е. Н. Баранова
ФГБОУ ВО КемГМУ МЗ РФ
Россия
Россия
О. А. Воросова
ФГБОУ ВО КемГМУ МЗ РФ
Россия
Россия
М. С. Карягина
ФГБОУ ВО КемГМУ МЗ РФ
Россия
Россия
К. А. Краснов
ФГБОУ ВО КемГМУ МЗ РФ
Россия
Россия
Список литературы
1. Lazarou J., Pomeranz B. H., Corey P. N. Incidence of adverse drug reactions in hospitalized patients // JAMA. 1998; 279: 1200-1205.
2. Lee W. M. Drug-induced acute liver failure // Clin Liver Dis. 2013; 17: 575-86. DOI: 10.1016/j.cld.2013.07.001.
3. Fontana R. J., Hayashi P. H., Gu J., et al. Idiosyncratic drug-induced liver injury is associated with substantial morbidity and mortality within 6 months from onset // Gastroenterology. 2014; 147: 96-108.e4. DOI: 10.1053/j.gastro.2014.03.045.
4. Sgro C., Clinard F., Ouazir K., et al. Incidence of drug-induced hepatic injuries: a French population-based study // Hepatology. 2002; 36: 451-5. DOI: 10.1053/jhep.2002.34857.
5. Bj?rnsson E. S., Bergmann O. M., Bj?rnsson H. K., et al. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland // Gastroenterology. 2013; 144: 1419-25. DOI: 10.1053/j.gastro.2013.02.006.
6. Stevens J. L., Baker T. K. The future of drug safety testing: expanding the view and narrowing the focus // Drug Discov Today. 2009; 14: 162-7. DOI: 10.1016/j.drudis.2008.11.009.
7. Nichols W. G., Steel H. M., Bonny T., et al. Hepatotoxicity observed in clinical trials of aplaviroc (GW873140) // Antimicrob Agents Chemother. 2008; 52: 858-65. DOI: 10.1128/AAC.00821-07.
8. Benza R. L., Barst R. J., Galie N., et al. Sitaxsentan for the treatment of pulmonary arterial hypertension: a 1-year, prospective, open-label observation of outcome and survival // Chest. 2008; 134: 775-82. DOI: 10.1378/chest.07-0767.
9. Wysowski D. K., Swartz L. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions // Arch Intern Med. 2005; 165: 1363-9. DOI: 10.1001/archinte.165.12.1363.
10. Ostapowicz G., Fontana R. J., Schiodt F.V., et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States // Ann Intern Med. 2002; 137: 947-954.
11. Stine J. G., Chalasani N. Chronic liver injury induced by drugs: a systematic review // Liver Int. 2015 Nov; 35 (11): 2343-2353. Doi: 10.1111/liv.12958.
12. Weinshilboum R. Inheritance and drug response // N Engl J Med. 2003; 348: 529-537.
13. Guengerich F. P. Common and uncommon cytochrome P450 reactions related to metabolism and chemical toxicity // Chem Res Toxicol. 2001; 14: 611-650.
14. Hunt C. M., Westerkam W. R., Stave G. M. Effect of age and gender on the activity of human hepatic CYP3A // Biochem Pharmacol. 1992; 44: 275-283.
15. Ikemoto S., Imaoka S., Hayahara N., Maekawa M., Funae Y. Expression of hepatic microsomal cytochrome P450s as altered by uremia // Biochem Pharmacol. 1992; 43: 2407-2412.
16. Guengerich F. P. Common and uncommon cytochrome P450 reactions related to metabolism and chemical toxicity // Chem Res Toxicol. 2001; 14: 611-650.
17. Moss A. J. The QT interval and torsades de pointes // Drug Saf. 1999; 21: Suppl 1: 5-10.
18. Thummel K. E., Slattery J. T., Ro H., et al. Ethanol and production of the hepatotoxic metabolite of acetaminophen in healthy adults // Clin Pharmacol Ther. 2000; 67: 591-599.
19. Yun C. H., Okerholm R. A., Guengerich F. P. Oxidation of the antihistamine drug terfenadine in human liver microsomes: role of cytochrome P-450 3A(4) in N-dealkylation and C-hydroxylation // Drug Metab Dispos. 1993; 21: 403-409.
20. Beaune P., Dansette P. M., Mansuy D., et al. Human anti-endoplasmic reticulum autoantibodies appearing in a drug-induced hepatitis are directed against a human liver cytochrome P-450 that hydroxylates the drug // Proc Natl Acad Sci U S A. 1987; 84: 551-555.
21. Lee W. M. Drug-Induced Hepatotoxicity // N Engl J Med. 2003, Jul 31; 349 (5): 474-485.
22. Trauner M., Meier P. J., Boyer J. Molecular pathogenesis of cholestasis // N Engl J Med. 1998; 339: 1217-1227.
23. Robin M.-A., Le Roy M., Descatoire V., Pessayre D. Plasma membrane cytochromes P450 as neoantigens and autoimmune targets in drug-induced hepatitis // J Hepatol. 1997; 26: Suppl 1: 23-30.
24. Jaeschke H., Gores G. J., Cederbaum A. I., Hinson J. A., Pessayre D., Lemasters J. J. Mechanisms of hepatotoxicity // Toxicol Sci. 2002; 66: 166-176.
25. Reed J. C. Apoptosis-regulating proteins as targets for drug discovery // Trends Mol Med. 2001; 7: 314-319.
26. Pessayre D., Berson A., Fromenty B., Mansouri A. Mitochondria in steatohepatitis // Semin Liver Dis. 2001; 21: 57-69.
27. Jonsson J. R., Edwards-Smith C. J., Catania S. C., et al. Expression of cytokines and factors modulating apoptosis by human sinusoidal lymphocytes // J Hepatol. 2000; 32: 392-398.
28. DeLeve L. D., Shulman H., McDonald G. B. Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (veno-occlusive disease) // Semin Liver Dis. 2002; 22: 27-42.
29. Brosens I., Johannisson E., Baulieu E.-E., et al. Oral contraceptives and hepatocellular carcinoma // Br Med J. 1986; 292: 1667-1668.
30. Watkins P. B. Drug metabolism by cytochromes P450 in the liver and small bowel // Gastroenterol Clin North Am. 1992; 21: 511-526.
31. Antoine D. J., Williams D. P., Kipar A., et al. High-mobility group box-1 protein and keratin-18, circulating serum proteins informative of acetaminophen-induced necrosis and apoptosis in vivo // Toxicol Sci. 2009; 112: 521-531.
32. Antoine D. J., Dear J. W., Lewis P. S., et al. Mechanistic biomarkers provide early and sensitive detection of acetaminophen-induced acute liver injury at first presentation to hospital // Hepatology. 2013; 58: 777-787.
33. Antoine D. J., Jenkins R. E., Dear J. W., et al. Molecular forms of HMGB1 and keratin-18 as mechanistic biomarkers for mode of cell death and prognosis during clinical acetaminophen hepatotoxicity // J Hepatol. 2012; 56: 1070-1079.
34. Wang K., Zhang S., Marzolf B. et al. Circulating microRNAs, potential biomarkers for drug-induced liver injury // Proc Natl Acad Sci USA. 2009; 106: 4402-4407.
35. Dear J. W., Antoine D. J., Starkey-Lewis P. et al. Early detection of paracetamol toxicity using circulating liver microRNA and markers of cell necrosis // Br J Clin Pharmacol. 2014; 77: 904-905.
36. McGill M. R., Sharpe M. R., Williams C. D. et al. The mechanism underlying acetaminophen-induced hepatotoxicity in humans and mice involves mitochondrial damage and nuclear DNA fragmentation // J Clin Invest. 2012; 122: 1574-1583.
37. Yu Y. C., Mao Y. M., Chen C. W. et al. Drug-induced Liver Injury (DILI) Study Group; Chinese Society of Hepatology (CSH); Chinese Medical Association (CMA). CSH guidelines for the diagnosis and treatment of drug-induced liver injury // Hepatol Int. 2017; 11: 221-241.
38. Church R. J., Watkins P. B. The transformation in biomarker detection and management of drug-induced liver injury // Liver Int. 2017; 37: 1582-1590.
39. Church R. J., Kullak-Ublick G. A., Aubrecht J. et al. Candidate biomarkers for the diagnosis and prognosis of drug-induced liver injury: An international collaborative effort // Hepatology. 2019, Feb; 69 (2): 760-773. DOI: 10.1002/hep.29802. Epub 2018 Jun 27.
40. Kullak-Ublick G. A., Andrade R. J., Merz M. et al Drug-induced liver injury: recent advances in diagnosis and risk assessment // Gut. 2017; 66: 1154-1164.
41. Fannin R. D., Russo M., O’Connell T. M. et al. Acetaminophen dosing of humans results in blood transcriptome and metabolome changes consistent with impaired oxidative phosphorylation // Hepatology. 2010; 51: 227-236.
42. Peta V., Tse C., Perazzo H. et al. Serum apolipoprotein A1 and haptoglobin, in patients with suspected drug-induced liver injury (DILI) as biomarkers of recovery // PLoS One. 2017; 12: e0189436.
43. Real M., Barnhill M. S., Higley C., Rosenberg J., Lewis J. H. Drug-Induced Liver Injury: Highlights of the Recent Literature // Drug Saf. 2019 Mar; 42 (3): 365-387. Doi: 10.1007/s40264-018-0743-2.
44. McGill M. R., Jaeschke H. Biomarkers of drug-induced liver injury: progress and utility in research, medicine, and regulation // Expert Rev Mol Diagn. 2018 Sep; 18 (9): 797-807. DOI: 10.1080/14737159.2018.1508998.
45. Fountain F. F., Tolley E., Chrisman C. R., Self T. H. Isoniazid hepatotoxicity associated with treatment of latent tuberculosis infection: a 7-year evaluation from a public health tuberculosis clinic // Chest. 2005; 128: 116-123.
46. Olsson R., Wiholm B. E., Sand C. et al. Liver damage from flucloxacillin, cloxacillin and dicloxacillin // J Hepatol. 1992; 15: 154-161.
47. Lucena M. I., Andrade R. J., Fern?ndez M. C., Pachkoria K., Pelaez G., Dur?n J. A., et al. Spanish Group for the Study of Drug?Induced Liver Disease (Grupo de Estudio para las Hepatopat?as Asociadas a Medicamentos (GEHAM)). Determinants of the clinical expression of amoxicillin?clavulanate hepatotoxicity: a prospective series from Spain // Hepatology. 2006; 44: 850-856.
48. Chalasani N. P., Hayashi P. H., Bonkovsky H. L., Navarro V. J., Lee W. M., Fontana R. J. Practice Parameters Committee of the American College of Gastroenterology. ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury // Am J Gastroenterol. 2014; 109: 950-966.
49. Lewis J. H., Stine J. G. Review article: prescribing medications in patients with cirrhosis - a practical guide // Aliment Pharmacol Ther. 2013; 37: 1132-1156.
50. Sulkowski M. S., Thomas D. L., Mehta S. H., Chaisson R. E., Moore R. D. Hepatotoxicity associated with nevirapine or efavirenz?containing antiretroviral therapy: role of hepatitis C and B infections // Hepatology. 2002; 35: 182-189.
51. Fontana R. J. Acute liver failure including acetaminophen overdose // Med Clin North Am. 2008; 92: 761-794. DOI: 10.1016/j.mcna.2008.03.005.
52. Padda M. S., Sanchez M., Akhtar A. J., Boyer J. L. Drug-induced cholestasis // Hepatology. 2011; 53: 1377-1387. DOI: 10.1002/hep.24229.
53. Danan G., Teschke R. RUCAM in Drug and Herb Induced Liver Injuryи // Int J Mol Sci. 2016, Jan; 17(1): 14. DOI: 10.3390/ijms17010014.
54. Wehling M. Non-steroidal anti-inflammatory drug use in chronic pain conditions with special emphasis on the elderly and patients with relevant comorbidities: management and mitigation of risks and adverse effects // Eur J Clin Pharmacol. 2014; 70: 1159-1172.
55. Day R. O., Graham G. G. Non-steroidal anti-inflammatory drugs (NSAIDs) // BMJ. 2013; 346: f3195.
56. Ungprasert P., Cheungpasitporn W., Crowson C. S, Matteson E. L. Individual non-steroidal anti-inflammatory drugs and risk of acute kidney injury: a systematic review and meta-analysis of observational studies // Eur J Intern Med. 2015; 26: 285-91.
57. Motola D., Vargiu A., Leone R., Cocci A., Salvo F., Ros B., et al. Hepatic adverse drug reactions: a case/non?case study in Italy // Eur J Clin Pharmacol. 2007; 63: 73-79.
58. Pillans P. I., Ghiculescu R. A., Lampe G., Wilson R., Wong R., Macdonald G. A. Severe acute liver injury associated with lumiracoxib // J Gastroenterol Hepatol. 2012; 27: 1102-1105.
59. Page M., Christin F., Hayi?Slayman D., Baillon J. J., Ber C. E., Delafosse B., et al. Acute liver failure due to a treatment by nimesulide: another case and review // Ann Fr Anesth Reanim. 2008; 27: 742-746.
60. Andrade R. J., Lucena M. I., Fern?ndez M. C. et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period // Gastroenterology. 2005; 129: 512-521.
61. Bjornsson E. Review article: drug-induced liver injury in clinical practice // Aliment Pharmacol Ther. 2010; 32: 3-13.
62. Hussaini S. H., Farrington E. A. Idiosyncratic drug-induced liver injury: an overview // Expert Opin Drug Saf. 2007; 6: 673-684.
63. Bessone F. Non-steroidal anti-inflammatory drugs: What is the actual risk of liver damage? // World J Gastroenterol. 2010, Dec 7; 16 (45): 5651-5661. DOI: 10.3748/wjg.v16.i45.5651
64. Donati M., Conforti A., Lenti M. еt al. Risk of acute and serious liver injury associated to nimesulide and other NSAIDs: data from drug-induced liver injury case-control study in Italy // Br J Clin Pharmacol. 2016; 82 (1): 238-248.
65. Garc?a Rodr?guez L. A., Williams R., Derby L. E., Dean A. D., Jick H. Acute liver injury associated with nonsteroidal anti-inflammatory drugs and the role of risk factors // Arch Intern Med. 1994; 154: 311-316.
66. P?rez Gutthann S., Garc?a Rodr?guez L. A. The increased risk of hospitalizations for acute liver injury in a population with exposure to multiple drugs // Epidemiology. 1993; 4: 496-501.
67. Licata A., Calvaruso V., Cappello M., Crax? A., Almasio P. L. Clinical course and outcomes of drug-induced liver injury: nimesulide as the first implicated medication // Dig Liver Dis. 2010; 42: 143-148.
68. Verma S., Kaplowitz N. Diagnosis, management and prevention of drug-induced liver injury.// Gut. 2009; 58: 1555-1564.
Рецензия
Для цитирования:
Плотникова Е.Ю., Баранова Е.Н., Воросова О.А., Карягина М.С., Краснов К.А. Лекарственная болезнь печени. Клинический случай цирроза печени на фоне приема нестероидных противовоспалительных препаратов. Лечащий Врач. 2020;(2):28-34. https://doi.org/10.26295/OS.2020.67.71.005
For citation:
Plotnikova E.Yu., Baranova E.N., Vorosova O.A., Кaryagina M.S., Krasnov K.A. liver disease. Clinical case of liver cirrhosis against the background of non-steroidal anti-inflammatory drugs. Lechaschi Vrach. 2020;(2):28-34. (In Russ.) https://doi.org/10.26295/OS.2020.67.71.005
Просмотров: 102
Послать статью по эл. почте 
